OpenAI President Greg Brockman Says AI Could Make Death an Optional Choice

TEHRAN, Nov 5 (OPA) — Speaking at the WSJ Tech event, OpenAI President Greg Brockman outlined the potential for artificial intelligence to revolutionize biology and human health. He noted that solving the problem of mortality and reducing disease-related suffering could become achievable as AI transforms medical research. Brockman emphasized that tangible impacts on healthcare and disease treatment should become more apparent within the next year to 18 months.

AI tools are increasingly integrated into biological research, spanning genetic sequence analysis, therapeutic target identification, and accelerated drug discovery. However, translating these digital breakthroughs into safe, effective clinical treatments still requires rigorous scientific validation and clinical trials. Brockman's perspective on human longevity aligns with earlier statements by billionaire Elon Musk, who has similarly described aging as a solvable biological mechanism.

Despite rapid advancements in computational biology, transitioning death into a voluntary choice remains a hypothetical horizon. Industry experts caution that Brockman's remarks do not signal an imminent breakthrough in immortality or a verified cure for the aging process. AI models currently assist researchers by processing vast datasets, but biological implementation faces extensive regulatory and physiological hurdles.

On the corporate front, Brockman addressed OpenAI's financial trajectory, acknowledging that the first half of 2026 proved difficult for the company. Despite early struggles, the rollout of new products and models successfully revitalized performance. Brockman reported that OpenAI's annualized revenue climbed 70 percent in the third quarter, while enterprise division revenue nearly doubled over the same period.